Analysts have set a price target for Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) at $87.43

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Get Your Free Report ) has been given a consensus rating of “Moderate Buy” by the fourteen analysts that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and thirteen have issued a buy recommendation on the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $87.43.

A number of brokerages have recently weighed in on RARE. Barclays reduced their price objective on shares of Ultragenyx Pharmaceutical from $83.00 to $81.00 and set an “overweight” rating on the stock in a research note on Monday, August 5th. Wedbush boosted their target price on shares of Ultragenyx Pharmaceutical from $43.00 to $46.00 and gave the stock a “neutral” rating in a research note on Friday, August 2nd. Robert W. Baird boosted their price objective on shares of Ultragenyx Pharmaceutical from $68.00 to $72.00 and gave the company an “outperform” rating in a research note on Friday, May 31st. Goldman Sachs Group boosted their price target on Ultragenyx Pharmaceutical from $67.00 to $76.00 and gave the stock a “buy” rating in a research report on Friday, August 2nd. Finally, Stifel Nicolaus raised their target price on Ultragenyx Pharmaceutical from $124.00 to $127.00 and gave the company a “buy” rating in a research report on Friday, May 31st.

See the latest stock analysis on RARE

Insider activity at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CEO Emil D. Kakkis sold 20,000 shares of the company’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $55.85, for a total transaction of $1,117,000.00. Following the sale, the chief executive officer now owns 2,223,985 shares in the company, valued at approximately $124,209,562.25. The transaction was disclosed in a filing with the SEC, which is available via this link. In other news, CEO Emil D. Kakkis sold 20,000 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $55.85, for a total value of $1,117,000.00. Following the transaction, the chief executive officer now directly owns 2,223,985 shares of the company’s stock, valued at $124,209,562.25. The transaction was disclosed in a legal filing with the SEC, which is accessible via this hyperlink. Also, EVP Karah Herdman Parschauer sold 9,806 shares of the business’s stock in a transaction that occurred on Wednesday, June 12th. The shares were sold at an average price of $45.00, for a total transaction of $441,270.00. Following the sale, the executive vice president now owns 57,981 shares in the company, valued at approximately $2,609,145. The disclosure for this sale can be found here. Insiders sold 50,481 shares of company stock worth $2,590,716 in the last quarter. 5.80% of shares are owned by company insiders.

Institutional Marketing of Ultragenyx Pharmaceutical

Hedge funds and other institutional investors have recently modified their holdings of the business. UMB Bank Na boosted its stake in Ultragenyx Pharmaceutical by 58.1% in the second quarter. UMB Bank now owns 958 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 352 shares during the last quarter. US Bancorp DE lifted its position in shares of Ultragenyx Pharmaceutical by 5.8% in the first quarter. US Bancorp DE now owns 7,143 shares of the biopharmaceutical company’s stock worth $334,000 after purchasing an additional 390 shares during the last quarter. Van ECK Associates Corp boosted its holdings in shares of Ultragenyx Pharmaceutical by 34.0% during the fourth quarter. Van ECK Associates Corp now owns 1,578 shares of the biopharmaceutical company’s stock worth $75,000 after purchasing an additional 400 shares during the period. Arizona State Retirement System boosted its position in Ultragenyx Pharmaceutical by 2.1% in the second quarter. Arizona State Retirement System now owns 20,744 shares of the biopharmaceutical company’s stock valued at $853,000 after purchasing an additional 434 shares in the last quarter. Finally, ProShare Advisors LLC boosted its stake in Ultragenyx Pharmaceutical by 8.7% in the first quarter. ProShare Advisors LLC now owns 6,074 shares of the biopharmaceutical company’s stock valued at $284,000 after buying an additional 486 shares during the period. Institutional investors and hedge funds own 97.67% of the company’s shares.

Ultragenyx Pharmaceutical trading down 2.1%

RARE opened at $55.24 on Friday. The company’s 50-day moving average is $48.85, and its 200-day moving average is $45.99. The stock has a market cap of $4.59 billion, a PE ratio of -6.88 and a beta of 0.56. Ultragenyx Pharmaceutical has a twelve month low of $31.52 and a twelve month high of $58.73.

Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Your Free Report ) last announced its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.52) earnings per share for the quarter, topping the consensus estimate of ($1.64) by $0.12. Ultragenyx Pharmaceutical had a negative return on equity of 266.02% and a negative net margin of 121.57%. The firm had revenue of $147.03 million for the quarter, compared to the consensus estimate of $123.20 million. In the same quarter last year, the company earned ($2.25) EPS. The company’s revenue for the quarter was up 35.7% year over year. As a group, analysts forecast that Ultragenyx Pharmaceutical will post -6.24 EPS for the current year.

Ultragenyx Pharmaceutical Company Profile

(Get a free report

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe and internationally. Its biologics include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.

Read more

Get news and reviews for Ultragenyx Pharmaceutical Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com’s FREE daily email newsletter.